always up to date

Latest news

PRINCIPAL INVESTIGATOR / PhD

Tom Vanden Berghe

Prof. Tom Vanden Berghe obtained a Master and a PhD in Science (Biotechnology) in 1999 and 2005, respectively. He was a postdoc at the VIB-UGent Center for Inflammation Research and became Assistant professor at UAntwerp and Guest professor at Gent University in 2018.

Prof. Tom Vanden Berghe is running two labs: Pathophysiology lab @UAntwerp and Ferroptosis and Inflammation Research lab @VIB-UGent. His mission is to perform applied research in the context of cell death/ferroptosis, inflammation and disease. The Vanden Berghe lab studies the mechanisms, diagnostics and intervention strategies in critical illness, brain injuries, chronic kidney disease, vascular calcification and bone metabolism. Along the in vivo validation of patented lead ferroptosis inhibitors, the Vanden Berghe lab also explores ferroptosis as novel anti-cancer therapy to eradicate therapy-resistant cancers. He has setup a multi-faceted ferroptosis platform covering novel lead ferroptosis inhibitors & genes, ferroptosis diagnostics, as well as ferroptosis nanomedicine anti-cancer therapeutics.

meet our team

Lab members

University of Antwerp
DSC 0353 copy

Tom Vanden Berghe, PhD

PRINCIPAL INVESTIGATOR

Assistant Professor @ UAntwerp
Guest Professor @ UGent

LEO0926 v2

Anja Verhulst, PhD

Team leader

Research coordinator
10% ZAP
Vascular calcification

2011 Benjamin Vervaet MR

Benjamin Vervaet, PhD

Team leader

Postdoctoral fellow
10% ZAP
Kidney disease

WhatsApp Image 2020 10 12 at 20.06.18

Behrouz Hassannia, PhD

Teamleader

Ferroptosis
Anti-cancer therapeutics

Britt

Britt Opdebeeck, PhD

Postdoctoral fellow

Mechanisms of vascular calcification

Lies c

Lies Moonen

PhD student

Nephrectomy induced repair

2017 Gerd 5416 MR

Gerd Schreurs

PhD student

Toxin induced nephropathy

WhatsApp Image 2020 09 29 at 20.52.20

Emily Van San

PhD student

Ferroptosis
Multiple sclerosis

image001 v2

Cedric Peleman

Phd student

Ferroptosis
Nonalcoholic fatty liver disease

ine 1

Ine Koeken

PhD student

Ferroptosis
Anti-cancer therapeutics

Astrid Van den Branden 2

Astrid Van den Branden

PhD student

Ferroptosis
Chronic kidney disease

B66F4250 A38D 4174 A14D C70CBF211BA3 1 201 a

Geraldine Veeckmans

PhD student

Ferroptosis
Ischemia/reperfusion injury

magali

Magali Walravens

PhD student

Ferroptosis
Mechanism lipid peroxidation

Saar DSC 3704

Saar Adriaensen

PhD Student

Endothelial cells
Vascular calcification

image copy

Elien Van Campen

PhD student

Nephrectomy
Regeneration

2007 Rita Marynissen MR

Rita Marinyssen

Technician

Administration
Biochemical analysis

2007 Hilde Geryl MR

Hilde Geryl

Technician

Experimental surgery
Bone histomorphometry
Biochemical analysis

2007 Ludwig Lamberts MR

Ludwig Lamberts

Technician

Biomedical Laboratory
Spectrometric Analyses

2013 Geert Dams

Geert Dams

Technician

Experimental surgery
Animal follow-up
Bone histomorphometry

Former lab members
WhatsApp Image 2020 08 31 at 16.42.30

Geoffrey Van Den Bergh

PhD student

Arterial stiffness in vascular calcification

Raphaelle

Raphaëlle Corremans

PhD student

Metformin
Chronic kidney disease

Perez Novo C

Claudina Perez Novo, PhD

Postdoctoral fellow

Ferroptosis
Anti-cancer therapeutics

39DEC982 ACC6 4DB0 AE61 A4A927A42882

Bartosz Wiernicki

PhD student

Ferroptosis
Immunogenicity

profielfoto

Samya Van Coillie

PhD student

Ferroptosis
Multi organ failure

Men grey

Sze Men Choi

Technician

Experimental surgery
Mouse manager
Standard lab analysis

2005 Geert Behets MR

Geert Behets, PhD

Teamleader

Postdoctoral fellow
Bone histomorphometry

DDW Pasfoto 2017 5207 VL v2

Dirk De Weerdt

Graphical support

principal investigator / PhD

Publications

More on Google Scholar
Title Cited by
2022
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
B Wiernicki, S Maschalidi, J Pinney, S Adjemian, T Vanden Berghe, ...
Nature communications 13 (1), 3676, 2022
15
2022
Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines
R Fernández-Acosta, C Iriarte-Mesa, D Alvarez-Alminaque, B Hassannia, ...
Molecules 27 (13), 3970, 2022
5
2022
Inhibiting RIPK1 kinase activity is protective in experimental models of COPD
HP Van Eeckhoutte, C Donovan, R Kim, H Khan, R Jayaraman, ...
ERJ Open Research 8 (suppl 8), 2022
0
2022
Luminescent human iPSC-derived neurospheroids enable modeling of neurotoxicity after oxygen–glucose deprivation
E Van Breedam, A Nijak, T Buyle-Huybrecht, J Di Stefano, M Boeren, ...
Neurotherapeutics 19 (2), 550-569, 2022
4
2022
Targeting ferroptosis protects against experimental (multi) organ dysfunction and death
S Van Coillie, E Van San, I Goetschalckx, B Wiernicki, B Mukhopadhyay, ...
Nature communications 13 (1), 1046, 2022
19
2022
Executioner caspases 3 and 7 are dispensable for intestinal epithelium turnover and homeostasis at steady state
F Ghazavi, J Huysentruyt, J De Coninck, S Kourula, S Martens, ...
Proceedings of the National Academy of Sciences 119 (6), e2024508119, 2022
6
2022
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD
HP Van Eeckhoutte, C Donovan, RY Kim, TM Conlon, M Ansari, H Khan, ...
European Respiratory Journal, 2022
0
2021
Necroptosis signaling promotes inflammation, airway remodeling, and emphysema in chronic obstructive pulmonary disease
Z Lu, HP Van Eeckhoutte, G Liu, PM Nair, B Jones, CM Gillis, ...
American journal of respiratory and critical care medicine 204 (6), 667-681, 2021
45
2021
Ferroptosis: biological rust of lipid membranes
B Hassannia, S Van Coillie, T Vanden Berghe
Antioxidants & Redox Signaling 35 (6), 487-509, 2021
17
2021
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL
T Oltean, E Van San, T Divert, T Vanden Berghe, X Saelens, J Maelfait, ...
Cell death & disease 12 (5), 1-10, 2021
8
2021
3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl) ethyl) benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating eg stroke
P Vandenabeele, T Vanden Berghe, K Augustyns, S Hofmans, ...
US Patent App. 16/967,871, 2021
1
2020
Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID‐19): autopsy reveals a ferroptosis signature
W Jacobs, M Lammens, A Kerckhofs, E Voets, E Van San, S Van Coillie, ...
ESC heart failure 7 (6), 3772-3781, 2020
70
2020
Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death
S Adjemian, T Oltean, S Martens, B Wiernicki, V Goossens, ...
Cell death & disease 11 (11), 1-15, 2020
48
2020
Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis
B Wiernicki, H Dubois, YY Tyurina, B Hassannia, H Bayir, VE Kagan, ...
Cell death & disease 11 (10), 922, 2020
58
2020
Emerging immune and cell death mechanisms in stroke: saponins as therapeutic candidates
L García-Pupo, E Van San, R Delgado-Hernández, T Vanden Berghe, ...
Brain, Behavior, & Immunity-Health, 100152, 2020
4
2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
MP Roberti, S Yonekura, CPM Duong, M Picard, G Ferrere, MT Alou, ...
Nature Medicine, 1-13, 2020
91
2020
Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
B Hassannia, E Logie, P Vandenabeele, T Vanden Berghe, ...
Biochemical pharmacology 173, 113602, 2020
73
2020
Nanoscopic X-ray imaging and quantification of the iron cellular architecture within single fibroblasts of Friedreich's ataxia patients
B De Samber, T Vanden Berghe, E Meul, S Bauters, M Seyrich, J Smet, ...
Journal of synchrotron radiation 27 (1), 185-198, 2020
3
2019
Targeting ferroptosis to iron out cancer
B Hassannia, P Vandenabeele, T Vanden Berghe
Cancer cell 35 (6), 830-849, 2019
981
2019
The molecular machinery of regulated cell death
D Tang, R Kang, T Vanden Berghe, P Vandenabeele, G Kroemer
Cell Research 29 (5), 347-364, 2019
974
total citations
28420
h-index
58
i10-index
91

Patents

Number Name Date
US9862678, WO2016075330, EP3218357 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death 2014-11-14
WO2019154795, EP3749645, CN112105601, US20210094909, 201980012162.8 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke 2018-02-07
WO2015110346, US9919048 Targeting of interleukin-1 and -18 signaling in treatment of septic shock 2014-01-21
EP22196811 New Ferroptosis Inhibitors 2022-09-21